Feb 22 (Reuters) - Moderna Inc said on Wednesday its experimental mRNA skin cancer vaccine in combination with Merck & Co Inc blockbuster drug Keytruda has received breakthrough therapy designation from the U.S. Food and Drug Administration (FDA). (Reporting by Khushi Mandowara in Bengaluru; Editing by Shinjini Ganguli)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
104.8 USD | -3.77% | +1.77% | +4.38% |
Apr. 24 | Sector Update: Health Care Stocks Slipping Late Afternoon | MT |
Apr. 24 | Moderna to Collaborate With OpenAI to Launch New Generation of Medicines | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+4.38% | 41.68B | |
+1.02% | 43.84B | |
+45.49% | 41.25B | |
-10.92% | 27.04B | |
+7.25% | 25.53B | |
-25.75% | 18.18B | |
-4.24% | 12.29B | |
+25.58% | 12.29B | |
+6.86% | 11.15B | |
-19.39% | 9.98B |
- Stock Market
- Equities
- MRNA Stock
- News Moderna, Inc.
- Moderna's combination skin cancer therapy receives FDA's breakthrough tag